MedTrace Logo

The Elderly ACS II Trial

NCT01777503 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1457

Last updated 2025-06-24

No results posted yet for this study

Summary

The objective of this study is to compare reduced-dose prasugrel and standard dose clopidogrel in patients older than 74 years with ACS, including non-ST-elevation (NSTEACS) and ST-elevation (STEMI) patients, undergoing early PCI. The primary endpoint of the trial will be the one-year composite of (all-cause)death, myocardial infarction, stroke and re-hospitalization due to cardiovascular reasons or bleeding.

Conditions

Interventions

DRUG

prasugrel

prasugrel 5 mg o.d.

DRUG

Clopidogrel

75 mg o.d.

Sponsors & Collaborators

  • ANMCO Italian Association of Hospital Cardiologist

    collaborator UNKNOWN

  • Italian Society of Invasive Cardiology

    collaborator OTHER

  • A. Manzoni Hospital

    collaborator OTHER

  • Azienda USL Reggio Emilia - IRCCS

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2017-01-25
Completion
2017-12-19

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01777503 on ClinicalTrials.gov